Therefore, we reasoned that our Fc-optimized mAb 8H8_SDIE will be a promising drug candidate for further evaluation in NSCLC patients, especially those who do not express PD-L1 or are unresponsive to ICI therapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.